Blood Sugar and Metabolic Health

A rare naturally occurring sugar found in figs and wheat that tastes like sugar but has almost no calories and actively improves blood sugar control — what the research shows

Allulose is a rare sugar that occurs naturally in small amounts in figs, wheat, raisins, and a few other plants. It looks and tastes like ordinary table sugar — about 70% as sweet — yet contributes almost no calories (roughly 0.2–0.4 kcal/g versus 4 kcal/g for sucrose) and does not raise blood glucose or insulin [4]. What makes it unusual among low-calorie sweeteners is that it does not merely replace sugar passively; studies show it actively lowers the spike in blood sugar that follows a meal, making it one of the few sweeteners that can actually improve glucose metabolism [1]. A 2023 meta-analysis found that consuming 5–10 g of allulose with a meal significantly reduced postprandial blood glucose compared to a control [1], and a 2024 meta-analysis in people with type 2 diabetes confirmed meaningful reductions in glucose area under the curve [5]. For anyone managing blood sugar — or simply trying to reduce sugar intake without switching to synthetic alternatives — allulose offers a compelling evidence base.

What Allulose Is and Where It Comes From

Allulose (also called D-allulose or D-psicose) is a monosaccharide — a simple sugar — that is a structural isomer of fructose, differing only in the arrangement of atoms around one carbon. It is present naturally in trace amounts in figs, raisins, jackfruit, kiwi, wheat, and brown sugar, though at concentrations too low to meaningfully consume through food alone. Commercial allulose is typically produced by enzymatically converting fructose from corn or other plant starch using the enzyme D-tagatose 3-epimerase, a process that yields a product chemically identical to naturally occurring allulose.

Allulose is absorbed from the small intestine similarly to other sugars — around 70–80% enters the bloodstream — but it is not metabolized for energy by human cells. The absorbed portion is excreted largely unchanged in the urine. This combination of normal absorption (no laxative effect from fermentation in the colon) and non-utilization for energy explains both its negligible caloric contribution and its excellent gastrointestinal tolerance compared to sugar alcohols like sorbitol or maltitol.

The US FDA has classified allulose as GRAS (Generally Recognized As Safe) and, unusually, has also ruled that it does not need to be counted toward total or added sugar content on US nutrition labels, acknowledging that it does not behave metabolically like conventional sugars.

How Allulose Lowers Blood Sugar

Allulose lowers postprandial blood glucose through several complementary mechanisms [3][4]:

Alpha-glucosidase inhibition. Allulose partially inhibits the intestinal enzyme that breaks down starch and sucrose into absorbable glucose. By slowing this step, it delays and blunts the glucose peak that follows a carbohydrate-containing meal — the same basic mechanism as the diabetes drug acarbose, but milder and without its gastrointestinal side effects.

GLP-1 stimulation. A 2018 study in Nature Communications showed that allulose stimulates the release of glucagon-like peptide-1 (GLP-1) from intestinal L-cells [3]. GLP-1 is the same hormone that injectable drugs like semaglutide (Ozempic) mimic; it increases insulin secretion in a glucose-dependent manner, suppresses glucagon, slows gastric emptying, and reduces appetite. Allulose appears to trigger this response naturally through gut sweet taste receptors and, at higher doses, through intestinal distension. The vagus nerve plays a key role in transmitting this signal to the brain and pancreas. Vagotomy (severing the vagus) or pharmacological blocking of the GLP-1 receptor eliminated the metabolic benefits of allulose in animal models — a clear demonstration that this pathway is essential to its effects.

Hepatic glycogen synthesis. Animal studies show that allulose enhances glycogen synthesis in the liver, which helps clear postprandial glucose from the bloodstream more efficiently and contributes to improved fasting glucose over time [4].

Appetite and food intake reduction. Via GLP-1 and central hypothalamic pathways, allulose reduces food intake in animal models. Human studies show modest but consistent reductions in appetite ratings after allulose consumption, consistent with the GLP-1 mechanism [3].

Blood Sugar Evidence in Humans

A 2023 systematic review and meta-analysis by Tani et al. pooled data from randomized crossover trials in healthy adults who consumed allulose alongside a glucose or carbohydrate load [1]. Both 5 g and 10 g doses produced a statistically significant reduction in the area under the glucose curve over 120 minutes post-meal. The effect was dose-responsive and consistent across the included studies.

A 2024 meta-analysis by Ayesh et al. focused specifically on people with type 2 diabetes, pooling six clinical trials and 126 participants [5]. Allulose significantly reduced postprandial glucose AUC (SMD: −0.67, 95% CI [−1.14, −0.20], p = 0.005) and time above range — the proportion of time blood glucose exceeded target levels. These are clinically meaningful endpoints for diabetes management.

For context, the reductions in post-meal glucose spike are roughly comparable in magnitude to adding resistant starch or vinegar to a meal — meaningful, but not dramatic enough to replace medical management of diabetes.

Body Composition Effects

A 12-week randomized double-blind placebo-controlled trial in 121 Korean adults with BMI ≥ 23 kg/m² tested two doses of allulose: 8 g/day (low dose) and 14 g/day (high dose), both added to usual diet [2]. The high-dose group showed significant reductions in body fat percentage, total abdominal fat area, and subcutaneous fat area measured by CT scan, compared to the sucralose placebo group. BMI also declined significantly in the high-dose group. Body weight changed modestly, as expected from a product with near-zero caloric content — the fat mass changes were out of proportion to the caloric difference, suggesting metabolic effects beyond simple calorie reduction.

The review by Hossain et al. summarized animal evidence showing that allulose reduces adipogenesis (fat cell formation), suppresses hepatic lipid accumulation, and improves lipid profiles in diet-induced obesity models [4]. These effects likely arise from the combination of improved insulin sensitivity, GLP-1-mediated changes in energy partitioning, and alterations in gene expression affecting fatty acid oxidation.

Practical Use

Allulose behaves remarkably like sugar in cooking — it caramelizes, browns, and dissolves in the same way, making it suitable as a direct replacement in baking, cooking, and beverages. This distinguishes it from erythritol (which doesn't brown well) and stevia (which has a distinct aftertaste at higher amounts). It is now available as a standalone sweetener and is appearing in commercial products targeted at people managing blood sugar.

A practical starting point is 5–10 g consumed with carbohydrate-containing meals to blunt the glucose response. Doses in research trials have ranged from 5 g to 15 g per serving with good tolerance; gastrointestinal side effects appear minimal at these levels compared to sugar alcohols, though very high single doses (above 30–40 g) may cause some digestive discomfort in sensitive individuals.

For people following a low-carbohydrate or ketogenic diet who wish to occasionally use a sweetener, allulose does not raise blood glucose or insulin, making it compatible with these approaches. Unlike erythritol, there is no current evidence associating allulose with adverse cardiovascular effects.

See our erythritol page for a comparison sweetener with a more complicated safety picture, our stevia page for the evidence on another natural low-calorie sweetener, and our GLP-1 natural boost page for other dietary approaches to stimulating this appetite- and glucose-regulating hormone.

Evidence Review

Meta-Analysis in Healthy Adults: Tani et al. 2023

Tani et al. conducted a systematic review and meta-analysis following PRISMA guidelines, searching PubMed and other databases for randomized controlled trials that measured postprandial blood glucose in healthy humans after allulose consumption [1]. Eligible studies were crossover or parallel-group RCTs providing a defined dose of allulose alongside a glucose or sucrose challenge.

The analysis included five studies. Both a 5 g and a 10 g allulose dose produced significantly smaller glucose AUC over the postprandial period compared to controls. The forest plots showed consistent effects across studies with low-to-moderate heterogeneity. No serious adverse events were reported in any included trial, and gastrointestinal tolerance was rated as good across all studies. The authors concluded that allulose attenuates postprandial blood glucose in a dose-dependent manner in healthy adults.

A limitation is that included studies were relatively short-term (single-meal challenges), and most were conducted in Japan by research groups with industry ties to Matsutani Chemical Industry, the major manufacturer of allulose. Independent replication in different populations and over longer periods strengthens confidence, and the 2024 type 2 diabetes meta-analysis (below) partly addresses this.

Meta-Analysis in Type 2 Diabetes: Ayesh et al. 2024

Ayesh et al. searched PubMed, Web of Science, Scopus, and Cochrane Library for RCTs assessing allulose in type 2 diabetes patients [5]. Six trials with 126 participants were included. The primary outcome was postprandial blood glucose AUC; secondary outcomes were time in range (TIR), time above range (TAR), fasting plasma glucose, and insulin AUC.

Key findings:

Glucose AUC: SMD −0.67 (95% CI [−1.14, −0.20], p = 0.005), moderate heterogeneity (I² = 58.3%)
TAR: significantly reduced in the allulose groups
No significant effect on fasting glucose or insulin AUC across the pooled studies

The moderate heterogeneity reflects variability in dose, study duration, and population characteristics. Overall the evidence supports allulose as a glycemic management tool, though the effect on long-term markers like HbA1c remains insufficiently studied at this point.

Fat Mass RCT: Han et al. 2018

Han and colleagues enrolled 121 Korean adults (BMI ≥ 23 kg/m²) in a 12-week double-blind placebo-controlled trial with three arms: sucralose placebo, low-dose allulose (4 g twice daily, 8 g/day), and high-dose allulose (7 g twice daily, 14 g/day) [2]. Participants consumed the study sweetener mixed into water with meals. The primary outcomes were body fat percentage and fat mass measured by dual-energy X-ray absorptiometry (DXA) and CT cross-sectional abdominal imaging.

Results in the high-dose group:

BMI: significant reduction vs. placebo (p < 0.05)
Body fat percentage: significantly decreased
Total abdominal fat area (CT): significantly decreased vs. placebo
Subcutaneous abdominal fat area (CT): significantly decreased vs. placebo

The low-dose group showed a trend toward fat reduction but did not reach statistical significance for most endpoints. Notably, the 14 g/day dose amounts to only about 5.6 kcal/day difference from placebo — far too small to explain fat loss through calorie deficit alone — supporting the conclusion that allulose exerts metabolic effects on fat storage and utilization independent of its caloric contribution. The proposed mechanisms include GLP-1 stimulation, improved insulin sensitivity, and altered hepatic lipid metabolism.

No significant adverse events were observed. Liver and kidney function markers remained normal throughout.

GLP-1 Mechanism: Iwasaki et al. 2018

Iwasaki et al. conducted a series of mechanistic experiments in rodent models to determine how allulose exerts metabolic benefits [3]. The key findings:

Oral allulose acutely increased plasma GLP-1 levels in normal and obese-diabetic rodents
This GLP-1 rise activated vagal afferent signaling — the mechanism by which gut-derived hormones communicate with the brain
Subchronic allulose treatment (administered at light-period onset) ameliorated hyperphagia, visceral obesity, and glucose intolerance specific to the light period
Pharmacological blockade of GLP-1 receptors with exendin 9-39 abolished the glucose-lowering effects
Vagotomy (surgical severing of the vagus nerve) also eliminated the metabolic benefits
Conditional knockout mice lacking GLP-1R specifically in vagal afferents showed blunted metabolic responses to allulose

The study also showed that chronic allulose exposure activated proopiomelanocortin (POMC) neurons in the arcuate nucleus of the hypothalamus — the same satiety neurons activated by leptin — which is consistent with reduced food intake observed in allulose-treated animals.

This mechanistic work in Nature Communications is important because it establishes a biologically plausible and well-characterized pathway connecting a dietary sweetener to meaningful metabolic benefits. GLP-1 release and vagal afferent signaling are validated therapeutic targets in type 2 diabetes and obesity, which lends credibility to the hypothesis that allulose's food-form effects in humans may be greater than its caloric insignificance would suggest.

Review of Metabolic Mechanisms: Hossain et al. 2015

Hossain et al. reviewed the body of animal and early human research on allulose across multiple metabolic domains [4]. Key findings summarized in the review:

Inhibition of intestinal alpha-glucosidase and sucrase, reducing carbohydrate hydrolysis and glucose absorption
Stimulation of hepatic glycogen synthesis via glucokinase activation, improving postprandial glucose clearance
Anti-adipogenic effects in cell culture and animal models: allulose suppressed lipid accumulation in 3T3-L1 adipocytes and reduced adipose tissue mass in diet-induced obese rodents
Anti-inflammatory effects on adipocytes: reduced secretion of pro-inflammatory adipokines including TNF-alpha and IL-6
Prevention of hepatic steatosis in high-fat-diet rodent models, associated with reduced hepatic lipogenesis gene expression

The review also noted that allulose appeared safe in multi-generational animal feeding studies with no evidence of organ toxicity, mutagenicity, or reproductive harm at high doses. These observations formed part of the evidence base for the FDA's subsequent GRAS determination for allulose in humans.

Safety and Tolerability

Across clinical trials, allulose has shown a favorable safety profile. Liver and kidney function markers, lipid panels, and complete blood counts have not been significantly altered by allulose supplementation at doses used in research (5–15 g per serving, up to 30 g/day). The FDA's GRAS determination and the unusual ruling excluding allulose from sugar labeling requirements reflect the agency's assessment that it is metabolically distinct from conventional sugars.

Gastrointestinal tolerance appears better than sugar alcohols like sorbitol or maltitol, because allulose is substantially absorbed in the small intestine rather than reaching the colon in large quantities to be fermented. At very high single doses (above 30–40 g), mild gastrointestinal discomfort has been reported in some individuals, but this threshold is well above typical usage amounts.

References

Allulose for the attenuation of postprandial blood glucose levels in healthy humans: A systematic review and meta-analysisYuma Tani, Masaaki Tokuda, Naoki Nishimoto, Hideto Yokoi, Ken Izumori. PLoS ONE, 2023. PubMed 37023000 →
A Preliminary Study for Evaluating the Dose-Dependent Effect of d-Allulose for Fat Mass Reduction in Adult Humans: A Randomized, Double-Blind, Placebo-Controlled TrialYoungji Han, Eun-Young Kwon, Mi Kyeong Yu, Seon Jeong Lee, Hye-Jin Kim, Seong-Bo Kim, Yang Hee Kim, Myung-Sook Choi. Nutrients, 2018. PubMed 29385054 →
GLP-1 release and vagal afferent activation mediate the beneficial metabolic and chronotherapeutic effects of D-alluloseYusaku Iwasaki, Mio Sendo, Katsuya Dezaki, Tohru Hira, Takehiro Sato, Masanori Nakata, Chayon Goswami, Ryohei Aoki, Takeshi Arai, Parmila Kumari, Masaki Hayakawa, Chiaki Masuda, Takashi Okada, Hiroshi Hara, Daniel J Drucker, Yuichiro Yamada, Masaaki Tokuda, Toshihiko Yada. Nature Communications, 2018. PubMed 29317623 →
Rare sugar D-allulose: Potential role and therapeutic monitoring in maintaining obesity and type 2 diabetes mellitusAkm Hossain, Fuminori Yamaguchi, Takayuki Matsuo, Ikuko Tsukamoto, Yukihiro Toyoda, Mikio Ogawa, Yorinobu Nagata, Masaaki Tokuda. Pharmacology and Therapeutics, 2015. PubMed 26297965 →
Impact of allulose on blood glucose in type 2 diabetes: A meta-analysis of clinical trialsHazem Ayesh, Sajida Suhail, Suhail Ayesh. Metabolism Open, 2024. PubMed 39583955 →